leadf
logo-loader
viewLexaGene Holdings Inc.
(
TSX-V:LXGOTCQB:LXXGF
)

LexaGene starts program to Identify UK and South African COVID Sequences

Lexagene Holdings (CVE: LXG- OTCQB: LXXGF) CEO Jack Regan joined Steve Darling from Proactive with news the company is planning to use their patented MiQLa system to investigate novel variants of the SARS-Cov-2 which is the pathogen that causes COVID-19.

Dr. Regan telling Proactive this investigation of the variants becomes very important to make sure vaccines will remain effective as the new strains appear to be about 70% more contagious, making containment that much more challenging.

Quick facts: LexaGene Holdings Inc.

Follow
TSX-V:LXG

Price: 0.405 CAD

Market Cap: $48.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

LexaGene MiQLab on display as the company highlights unique features at WVC...

LexaGene CEO Dr. Jack Regan joined Steve Darling from Proactive on the floor of the 93rd annual WVC conference. This conference in Las Vegas is a gathering of veterinary marketplace leaders. Regan, who is a highlight speaker at the event, shared more with Proactive about his topic “In-Clinic...

2 weeks, 1 day ago

2 min read